KIDS Stock Dips 13%, But Wall Street Remains Bullish

Forward-Looking Analysis

Analysts project Orthopediatrics (KIDS) will report Q2 2026 revenue of $68.47 million, with a consensus estimate range of $67.90 million to $68.80 million. This represents a significant increase from the Q1 2026 actual revenue of $59.36 million. Earnings per share (EPS) are estimated at -$0.32, with a broader forecast range of -$0.40 to -$0.19, showing an improvement from the Q1 EPS of -$0.45. Over the past three months, revenue and EPS estimates for the fiscal year have remained unchanged, correlating with a 12.9% decline in stock price, which some analysts view as a potential buying opportunity. Despite recent estimate stability, Wall Street sentiment remains overwhelmingly positive. Out of four recent analyst ratings, three are "Buy" and one is "Hold," resulting in a "Strong Buy" consensus. The average 12-month price target is set at $23.00, implying a 21.89% upside from the current price of $18.87. Price targets range from $20.00 to $35.00, with notable bullish views from Needham ($30) and Lake Street ($34). Historically, KIDS stock has tended to move up by 3.18% in the 10 days leading up to earnings, though post-earnings reactions have been muted. The company has beaten sales estimates in the past 12 months, outperforming its industry peers in revenue prediction accuracy.

Historical Performance Review

Orthopediatrics delivered strong results in Q1 2026, reporting revenue of $59.36 million and generating a gross profit of $43.39 million. The company posted a net loss of $10.69 million, resulting in an EPS of -$0.45. Despite the net loss, the gross profit margin demonstrated operational efficiency. The Q1 performance marked a positive trend following a record full-year 2025 revenue of $236.3 million, which represented a 15% year-over-year increase. The company also achieved its first quarter of positive free cash flow in history during Q4 2025, signaling improving financial health and operational maturity.

Additional News

Orthopediatrics continues to expand its market presence through product innovation and strategic engagement. On April 30, 2026, the company announced the expansion of its Specialty Bracing portfolio with the TRAXIO Halo Gravity Traction System. Earlier, on February 3, 2026, partner iotaMotion received FDA clearance for its iotaSOFT® cochlear implant insertion system for patients aged four and older, broadening the enabling technology market opportunity. The company participated in major investor events, including the Goldman Sachs 47th Annual Global Healthcare Conference in May and the Needham Virtual Healthcare Conference in March. Following a record full-year 2025 revenue of $236.1 million and the generation of $10 million in free cash flow in Q4 2025, Orthopediatrics issued 2026 financial guidance targeting record Adjusted EBITDA. CEO David Bailey and CFO Fred Hite have been active in presenting these results to investors, highlighting improved operating cash flow and strategic growth initiatives.

Summary & Outlook

Orthopediatrics exhibits improving financial health, evidenced by record 2025 revenue and historic free cash flow generation. The Q2 outlook is positive, with projected revenue growth to $68.47 million and narrowing losses. Key catalysts include new product launches like the TRAXIO system and FDA-cleared enabling technologies. While the company remains unprofitable on a net basis, the trajectory toward Adjusted EBITDA positivity and strong analyst consensus supports a bullish stance. The stock's recent dip presents a potential entry point, with significant upside potential relative to current valuations.